How We Approach Difficult to Eradicate Helicobacter pylori

Gastroenterology. 2022 Jan;162(1):32-37. doi: 10.1053/j.gastro.2021.10.048. Epub 2021 Nov 3.

Authors

Erick A Argueta¹, Steven F Moss²

Affiliations

¹ Department of Medicine, Division of Gastroenterology, Alpert Medical School of Brown University, Providence, Rhode Island.
² Department of Medicine, Division of Gastroenterology, Alpert Medical School of Brown University, Providence, Rhode Island. Electronic address: steven_moss@brown.edu.

PMID: 34743914
DOI: 10.1053/j.gastro.2021.10.048

No abstract available

MeSH terms

Anti-Bacterial Agents / adverse effects
Anti-Bacterial Agents / therapeutic use*
Drug Hypersensitivity / etiology
Drug Resistance, Bacterial
Drug Therapy, Combination
Helicobacter Infections / diagnosis
Helicobacter Infections / drug therapy*
Helicobacter Infections / microbiology
Helicobacter pylori / drug effects*
Helicobacter pylori / pathogenicity
Host-Pathogen Interactions
Humans
Microbial Sensitivity Tests
Patient Education as Topic
Proton Pump Inhibitors / adverse effects
Proton Pump Inhibitors / therapeutic use*
Remission Induction
Risk Factors
Treatment Failure

Substances

Anti-Bacterial Agents
Proton Pump Inhibitors